← Leaderboards
Mark Manzano
Univ Of Arkansas For Med Scis
$1,915,360
Attributed
$2,125,527
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,125,527 · 5
By mechanism
R21$813,737 · 2
R01$583,289 · 1
K22$500,501 · 1
P30$228,000 · 1
Top collaborators
- James Craig Forrest1 shared
Most similar at Univ Of Arkansas For Med Scis
Same institution · by research overlap
- Lu Dai$795,513
- Karen E. Beenken$909,870
- Robert L Eoff$4,489,303
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsProgramsLymphoma CellHuman Herpesvirus 8ViralAcquired Immunodeficiency SyndromeMalignant NeoplasmsGenetic TranscriptionNeoplastic CellGenesTumorTranscriptomeCell LineOncogenicB-Cell LymphomasPrimary Effusion LymphomaLymphomaProteinsB Lymphoid MalignancyMutationMaintenanceBiologyLeftCell Survival
Grant awards (8)
Epigenetic Regulation of KSHV Latency$583,289
R01 · FY2025 · DE · contact PI
Lytic viral genes in the pathogenesis of oncogenic gammaherpesviruses$420,335
R21 · FY2025 · AI
Microscopy and Cellular Imaging Core$228,000
P30 · FY2024 · GM · contact PI
Role of a latent OriLyt RNA in KSHV latency in primary effusion lymphoma$178,819
R21 · FY2024 · CA · contact PI
Role of a latent OriLyt RNA in KSHV latency in primary effusion lymphoma$214,583
R21 · FY2023 · CA · contact PI
Oncogenic Roles and Therapeutic Potential of MCL1 Addiction in Primary Effusion Lymphoma$158,397
K22 · FY2022 · CA · contact PI
Oncogenic Roles and Therapeutic Potential of MCL1 Addiction in Primary Effusion Lymphoma$158,397
K22 · FY2021 · CA · contact PI
Oncogenic Roles and Therapeutic Potential of MCL1 Addiction in Primary Effusion Lymphoma$183,707
K22 · FY2020 · CA · contact PI